TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04308278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2LEBV® / 2LXFS®
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Study: NCT04946994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: The participant will walk/jog for 50 continuous minutes at 55% VO2peak. For resistance exercise, the initial goal will be to complete 3 sets of 8-10 repetitions of 4 exercises at low intensity (50% 1-RM) and then progress to moderate intensity (70-80% 1-RM). Exercise intensity will increase every 4 weeks or when participants can complete more than 8 repetitions with proper form at the prescribed weight.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CME
Description: The participant will walk/jog for 50 continuous minutes at 55% VO2peak. For resistance exercise, the initial goal will be to complete 3 sets of 8-10 repetitions of 4 exercises at low intensity (50% 1-RM) and then progress to moderate intensity (70-80% 1-RM). Exercise intensity will increase every 4 weeks or when participants can complete more than 8 repetitions with proper form at the prescribed weight.
Study: NCT06652438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revumenib
Description: day 1- 28 per cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: day 1- 28 per cycle
Study: NCT06648356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Description: Neuromuscular electrical stimulation (NMES) is applied during an isometric contraction. The NMES uses a symmetrical biphasic rectangular pulse (50Hz frequency and 300 µs phase width) delivered through an Enraf Nonius TensMed S82 electrostimulator. Two 5x9 cm electrodes are placed on the hamstrings, and participants adjust the current to a moderate-strong, yet painless, contraction level. During the intervention, one researcher maintains the stretch position while another researcher controls the current intensity and monitors the timing of both stretching and contractions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contract-Relax PNF (crPNF)
Description: The crPNF Group engages in an isolated contract-relax proprioceptive neuromuscular facilitation (crPNF) stretching protocol. Participants are positioned in a long sitting posture with maximum knee extension until they feel a moderate-strong stretch sensation, without pain. Each stretch lasts for 20 seconds, followed by a 5-second maximal voluntary isometric contraction of the hamstrings. Participants complete three cycles of stretch and contraction. One researcher maintains the stretch position while a second researcher controls the timing of the stretching and contractions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contract-Relax PNF (crPNF)
Description: The crPNF Group engages in an isolated contract-relax proprioceptive neuromuscular facilitation (crPNF) stretching protocol. Participants are positioned in a long sitting posture with maximum knee extension until they feel a moderate-strong stretch sensation, without pain. Each stretch lasts for 20 seconds, followed by a 5-second maximal voluntary isometric contraction of the hamstrings. Participants complete three cycles of stretch and contraction. One researcher maintains the stretch position while a second researcher controls the timing of the stretching and contractions.
Study: NCT05423197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-panitumumab IV
Description: Subjects will be given a bolus of 1.0 mCi (range 0.8 - 1.2 mCi) of 89Zr-panitumumab before undergoing further standard of care diagnostic evaluation of the lesions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab
Description: Panitumumab 30mg will be given orally
Study: NCT06598592

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video-Emergency
Description: Video Emergency Call using a webbased platform

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Audio-Emergency Call
Description: Audio Emergency Call
Study: NCT06661590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Messaging
Description: Dieticians will evaluate nutritional messages created by LLM and Human Experts.
Study: NCT06662526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trace lithium dose plus treatment as usual
Description: Subjects assigned to the active arm will receive 50 mg of lithium per day, for five years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill plus treatment as usual
Description: Patients will receive a placebo pill plus treatment as usual by their clinical providers
Study: NCT06664697

Intervention type: DEVICE
Intervention: Cochlear Implantation with Robotic-Assisted Insertion System
Description: The purpose of the study is to collect additional safety data in retrospective and prospective subjects who receive a cochlear implant using the iotaSOFT Insertion System.

Intervention type: DEVICE
Intervention: Cochlear Implantation with Robotic-Assisted Insertion System
Description: The purpose of the study is to collect additional safety data in retrospective and prospective subjects who receive a cochlear implant using the iotaSOFT Insertion System.
Study: NCT06666140

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasonic elastography
Description: The measurement of diaphragmatic stiffness by shear waves is performed with a high-frequency linear ultrasound probe, intercostally, during apneas lasting a few seconds.~After quantitative diaphragm thickness measurements, the ultrasound probe positioning is unchanged and regions of interest are placed in the patient's diaphragm thickness as well as in the adjacent liver or spleen (baseline). A stiffness result is obtained in kPa.~The elastography measurement extends the duration of the ultrasound scheduled as part of patient care by only 10 minutes.~The examination is painless and non-invasive.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasonic elastography
Description: The measurement of diaphragmatic stiffness by shear waves is performed with a high-frequency linear ultrasound probe, intercostally, during apneas lasting a few seconds.~After quantitative diaphragm thickness measurements, the ultrasound probe positioning is unchanged and regions of interest are placed in the patient's diaphragm thickness as well as in the adjacent liver or spleen (baseline). A stiffness result is obtained in kPa.~The elastography measurement extends the duration of the ultrasound scheduled as part of patient care by only 10 minutes.~The examination is painless and non-invasive.
Study: NCT06665048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone HCl
Description: Administer oxycodone hydrochloride (0.1 mg/kg) intravenously half an hour before surgery.
Study: NCT05296395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus Plantarum 299v in fermented oat drink
Description: The intervention is a probiotic lactobacillus that is contained in food products in the US

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Heat-Killed Placebo control fermented drink
Description: The intervention is the GoodBelly StraightShort that has been treated to heat kill all Lp299v
Study: NCT05490641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Glucose-based biofeedback
Description: Participants will wear a Fitbit activity tracker and receive personalized text messages over a 12-week period. During the first 4 weeks of the study period, participants will also wear a continuous glucose monitor to check their glucose levels in real-time and receive text messages based on their activity and glucose data.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard feedback
Description: Participants will wear a Fitbit activity tracker and receive non-personalized text messages over a 12-week period.
Study: NCT06421077

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transauricular auricular vagus nerve stimulation
Description: transauricular auricular vagus nerve stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transauricular auricular vagus nerve stimulation
Description: transauricular auricular vagus nerve stimulation
Study: NCT05799326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levofloxacin simulant
Description: Levofloxacin simulant is placebo.
Study: NCT05147805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Palmitil
Description: Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.
Study: NCT06084221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Data-Driven Decision Making (DDDM)
Description: The intervention consists of providing real-time data on overdose touchpoints to OFRs and training in DDDM for continuous quality improvement cycles, leading to improved OFR recommendations and implementation of overdose prevention strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overdose-prevention strategies inventory
Description: A list of overdose prevention and harm reduction strategies will be provided to OFRs for possible implementation, depending on local needs and final dashboard development.
Study: NCT05462834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compressed Air
Description: Participants will be instructed to use compressed air during sleep as a placebo control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compressed Air
Description: Participants will be instructed to use compressed air during sleep as a placebo control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental Oxygen
Description: Participants will be instructed to use supplemental oxygen at rate of 2lpm during sleep.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental Oxygen
Description: Participants will be instructed to use supplemental oxygen at rate of 2lpm during sleep.
Study: NCT06478121

Intervention type: OTHER
Intervention: Data and Blood collection
Description: Data and Blood collection

Intervention type: OTHER
Intervention: Data and Blood collection
Description: Data and Blood collection

Intervention type: OTHER
Intervention: MRI
Description: MRI (optional)

Intervention type: OTHER
Intervention: MRI
Description: MRI (optional)
Study: NCT06000319

Intervention type: BIOLOGICAL
Intervention: Natural Matrix Protein (NMP) Fibers
Description: human bone allograft

Intervention type: BIOLOGICAL
Intervention: Natural Matrix Protein (NMP) Fibers
Description: human bone allograft

Intervention type: PROCEDURE
Intervention: Lumbar interbody fusion
Description: Procedure that involves removing the intervertebral disk from the disk space between between 2 or more vertebrae between L1 and S1. When the disk space has been cleared out, the surgeon fills the void between the vertebrae with a bone void filler.

Intervention type: PROCEDURE
Intervention: Cervical interbody fusion
Description: Procedure that involves removing the intervertebral disk from the disk space between between 2 or more vertebrae between C2 and T1. When the disk space has been cleared out, the surgeon fills the void between the vertebrae with a bone void filler.
Study: NCT06039189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered as subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Guselkumab
Description: Guselkumab will be administered as subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as subcutaneous injection.
Study: NCT04836559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813
Description: JNJ-40411813 will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JNJ-40411813
Description: JNJ-40411813 will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.
Study: NCT06768671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonelokimab
Description: Open label
Study: NCT05593328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: IV infusion
Study: NCT04959474

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Given standard dietary recommendations

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SABR

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SABR

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection
Description: Undergo surgical resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection
Study: NCT06646211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib , Thiotepa
Description: First 1-4 cycle~Drug: Thiotepa~* 40mg/m2，d1 each 21-day cycle from cycle 1 for up to 4 cycle Drug: Zanubrutinib~* Zanubrutinib will be given at a dose of 160mg，bid，d1-d21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate , Thiotepa and Zanubrutinib
Description: Cycle 5 - 10 Drug: Methotrexate~* Intravenous methotrexate at 3.5g/m2 for 6 hours will be given on day 1 each 21-day cycle 【Leucovorin Calcium (CF): 15mg/m², rescue begins 12 hours after the infusion of methotrexate (MTX) ends, administered every 6 hours until the MTX plasma concentration is ≤ 0.1 μmol·L-¹ at 48 hours; plasma concentration monitoring time points: 0, 6, 24, 48, 72 hours.】 Other Names: MTX Drug: Thiotepa~* 40mg/m2，d1 each 21-day cycle from cycle 5 for up to 10 cycle Drug: Zanubrutinib Zanubrutinib will be given at a dose of 160mg，bid，d1-d21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASCT±Zanubrutinib
Description: Consolidation / maintenance treatment Patients who achieve a Complete Response (CR) or Partial Response (PR) after the ZT/ZMT treatment will enter consolidation/maintenance therapy.~Patients age ≤65 years old will undergo Autologous Stem Cell Transplantation (ASCT, with a recommended conditioning regimen that includes Thiotepa), followed by 6 months of maintenance treatment with zanubrutinib.~Patients age \> 65 will receive 6 months of maintenance treatment with zanubrutinib.~\*The study permits the prophylactic use of Granulocyte Colony-Stimulating Factor (G-CSF). For detailed usage, please refer to the guidelines from the National Comprehensive Cancer Network (NCCN) or the Chinese Society of Clinical Oncology (CSCO)
Study: NCT06646705

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Saliva obtaining
Description: The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
Study: NCT06584565

Intervention type: OTHER
Intervention: microbiome; metabolomics; proteomics
Description: post-stroke change of microbiome; metabolomics; proteomics

Intervention type: OTHER
Intervention: microbiome; metabolomics; proteomics
Description: post-stroke change of microbiome; metabolomics; proteomics
Study: NCT06140485

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NW Low-Glu®
Description: One NW Low-Glu® capsule contains Mas Cotek powdered Extract 300 mg (from leaves of Ficus deltoidea Jack by aqueous solvent extraction) + Cinnamomum cassia L. powdered Extract 100 mg + Black seed powdered extract 250 mg (from seeds of Nigella sativa L. by 70% hydro-alcoholic extraction).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients in the active comparator arm will receive a total of 2000 mg of metformin per day.
Study: NCT05028647

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality training
Description: one hour a day for 5 days of engagement in tasks proposed by a specially crafted software through a VR device (Oculos)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Augmented reality training
Description: one hour a day for 5 days of engagement in tasks proposed by a specially crafted software through a AR device (tablet)
Study: NCT05645809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MONOFIX® PGCL
Description: An absorbable suture made of polyglycapron (PGCL) used for soft tissue suture.
Study: NCT06665074

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin (E. coli O:113, Reference Endotoxin)
Description: Dosage of endotoxin is 0.8 ng/Kg body Weight
Study: NCT05645809

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Quill Monoderm™
Description: An absorbable suture made of polyglactin used for soft tissue suture.
Study: NCT04321915

Intervention type: OTHER
Group type: OTHER
Intervention: Analysis of intestinal microbiota in autism spectrum desorder
Description: This analysis permit to describe the diversity and composition of microbiota and the factors that may influence them. In fact, the gut microbiota plays a key role in regulating the gut-brain axis
Study: NCT06665074

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Endotoxin (E. coli O:113, Reference Endotoxin)
Description: Dosage of endotoxin is 0.8 ng/Kg body Weight

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline (Placebo)
Description: Volume of saline to be the same as volume of endotoxin

Intervention type: OTHER
Group type: OTHER
Intervention: Saline (Placebo)
Description: Volume of saline to be the same as volume of endotoxin
Study: NCT06664970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine or Ruxolitinib combined with Selinexor
Description: 1. The initial dose of Selinexor combined with Azacitidine for the treatment of MDS patients is 40mg QW, adjusted according to blood tests, with the highest dose ≤ 60mg QW.~   Azacitidine: The initial dose is 75 mg/m ², administered subcutaneously or intravenously, with a cycle of 1-7 days and 28 days until ineffective or intolerant.~2. Selinexor combined with Ruxolitinib for the treatment of patients with MPN symptoms: Selinexor dose: 40mg QW; Adjust according to the blood count, with a maximum dose of ≤ 60mg QW.~Initial dose of Ruxolitinib: platelet count\>100 × 109/L before enrollment, initial dose is 15 mg BID; Platelets range from 50-100 × 109/L, with an initial dose of 10 mg BID. Until ineffective or intolerant.
Study: NCT06665100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUL-042
Description: Pam2 : ODN (PUL-042) PUL-042 Inhalation Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile Saline for Inhalation
Study: NCT04959474

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sentinel Lymph Node Biopsy
Description: Undergo sentinel lymph node biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy
Description: Undergo sentinel lymph node biopsy
Study: NCT06605950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KarXT
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KarXT
Description: Specified dose on specified days
Study: NCT04959474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Undergo a caloric restriction diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06605950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KarXT
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KarXT
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KarX-EC
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KarX-EC
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Specified dose on specified days
Study: NCT06259903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD-18
Description: Subcutaneous Administration of MD-18 in Healthy Subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD-18
Description: Subcutaneous Administration of MD-18 in Healthy Subjects.